increased survival

Showing 1 posts of 1 posts found.


Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …

Latest content